Yeda Research and Develpment & Co. Ltd

Teva Pharmaceutical Industries Limited

Sharon Cohen-Vered

Adrian Gilbert

Ety Klinger

Milka Linenberg

Vera Weinstein

Esmira Naftali

Rivka Riven-Kreitman

Ramon F Joubran

The subject invention provides a pharmaceutical composition comprising an aqueous carrier; from 0.1 mg/ml to 20 mg/ml of the composition of a pharmaceutically acceptable salt of a peptide having the structural formula-Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Glu Glu Trp Ile Gly-;and a substituted &#x3b2;-cyclodextrin in an amount effective to dissolve the peptide in the aqueous carrier, wherein the composition has a pH between 4 and 9, a process for preparation, and a method of alleviating symptoms of systemic lupus erythematosus (SLE) in a human subject comprising administering to the human subject the pharmaceutical composition.

Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus

Pharmaceutical compositions useful for treating autoimmune diseases in a mammal comprising as an active ingredient a therapeutically effective amount of Copolymer 1, and microcrystalline cellulose are disclosed. Processes for the manufacture of such compositions are also disclosed.

Oral, nasal and pulmonary dosage formulations of copolymer 1

Growing community of inventors

Kfar Sava, Israel

Sharon Cohen-Vered